Testosterone News and Research

Latest Testosterone News and Research

Frisky old men - still keen and active: Sex study

According to the latest Australian study, men at 75 and older have not said good bye to their sex lives yet. They found that nearly one third of these older men were sexually active at least once a year -- including about 1 in 10 men aged 90 to 95. Many of these men have agreed that they would want more of sex and those not sexually active are blaming health issues, low testosterone or lack of partners. The findings appear in the Dec. 7 issue of the Annals of Internal Medicine.

6 Dec 2010

Finger length may predict prostate cancer

In a new study published in the British Journal of Cancer, researchers have revealed a connection between finger length and prostate cancer. It says that men whose ring fingers are longer than their index fingers are more likely to develop prostate cancer.

1 Dec 2010

Men with long index fingers at lower risk of prostate cancer

Men who have long index fingers are at lower risk of prostate cancer, a new study published today in the British Journal of Cancer has found.

1 Dec 2010

New findings could drive medical advances in genetic disorders that cause infertility

A hormone responsible for the onset of puberty can end up stuck in the wrong part of the body if the nerve pathways responsible for its transport to the brain fail to develop properly, according to research funded by the Biotechnology and Biological Sciences Research Council (BBSRC).

30 Nov 2010

Medivation, Astellas enroll 1,199 patients in MDV3100 Phase 3 AFFIRM study in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.

30 Nov 2010

FDA approves Axiron topical solution CIII for testosterone replacement therapy in men

Acrux , a drug delivery company that develops and commercializes patented pharmaceutical products for global markets, and Eli Lilly Company today announced that the United States Food and Drug Administration (FDA) has approved the Axiron® topical solution CIII for testosterone replacement therapy in men. Axiron is the first testosterone topical solution approved for application via an underarm applicator.

29 Nov 2010

ESF report: Reduced male fertility may contribute to low birth rates

Reduced male fertility may be making it even harder for couples to conceive and be contributing to low birth rates in many countries, reveals a new European Science Foundation (ESF) report launching today at the IPSEN meeting in Paris.

28 Nov 2010

Study suggests less than 10% of UK adults with CAH receive specialist endocrine care

A new study suggests that less than 10% of the estimated 3,591 adults in the UK with the genetic condition congenital adrenal hyperplasia (CAH) receive specialist endocrine care, and that there is no standard treatment for these patients.

26 Nov 2010

Study finds gender difference in brain function of schizophrenics

Schizophrenia is a mental disorder that differs between the sexes in terms of age at onset, symptomatology, response to medication, and structural brain abnormalities. Now, a new study from the Universit- de Montr-al shows that there is gender difference between men and women's mental ability with women performing better than men.

20 Nov 2010

Merck wins third FOSAMAX bellwether trial

Merck & Co., Inc. today said a federal court jury in New York found in its favor in the Graves v. Merck case, rejecting the claims of a Florida woman who blamed her dental and jaw related problems on her FOSAMAX use. With today's verdict, Merck has won three of the first four bellwether cases in the FOSAMAX litigation.

20 Nov 2010

Antares advances VIBEX QS platform for highly-viscous drug injection

Antares Pharma, Inc., a leader in self-injection drug delivery technology, today announced the latest advancement in its proprietary line of VIBEX auto-injectors.

20 Nov 2010

BioSante announces sale of oncolytic virus technology to Cold Genesys

BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.

18 Nov 2010

Men treated with hormone-based therapy for prostate cancer face higher risk of colorectal cancer: Study

Men treated with hormone-based therapy for prostate cancer faced a 30 percent to 40 percent higher risk of colorectal cancer, compared to patients who did not receive this treatment, according to a new study.

16 Nov 2010

GTx presents preclinical studies of GTx-758 and GTx-230 for treatment of cancer

GTx, Inc. announced the presentation of preclinical studies evaluating GTx-758, a selective estrogen receptor alpha agonist being developed for first line treatment of advanced prostate cancer, and GTx-230, a novel microtubule polymerization inhibitor.

15 Nov 2010

Using mild painkillers during pregnancy can increase risk of male reproductive disorders

New evidence has emerged that the use of mild painkillers such as paracetamol, aspirin and ibuprofen, may be part of the reason for the increase in male reproductive disorders in recent decades.

10 Nov 2010

New study reveals finger length can indicate high testosterone levels

Potential investors might wish to examine the fingers of their financial advisor prior to signing over any savings. A new study from Concordia University has found the length between the second and fourth finger is an indicator of high levels of prenatal testosterone, risk-taking and potential financial success in men.

10 Nov 2010

$Long-term androgen deprivation therapy increases risk of fracture in older men with prostate cancer$

Long-term androgen deprivation therapy increases risk of fracture in older men with prostate cancer

Men with history of fracture and comorbidities are at an increased risk of fracture after long-term use of androgen deprivation therapy, and initiating this therapy should be carefully considered in older men with localized prostate cancer.

9 Nov 2010

GTx third quarter net loss decreases to $8.6 million

GTx, Inc. today reported financial results for the third quarter of 2010. The net loss for the quarter ended September 30, 2010 was $8.6 million compared with a net loss of $12.8 million for the quarter ended September 30, 2009. For the nine months ended September 30, 2010, GTx reported net income of $22.8 million compared with a net loss of $35.4 million for the same period in 2009.

9 Nov 2010

Research may help develop new therapies for aggressive prostate cancer

A monoclonal antibody targeting a well known cell surface protein inhibited prostate cancer growth and metastasis in an aggressive form of the disease that did not respond to hormone therapy, according to a study by researchers with the UCLA Department of Urology and UCLA's Jonsson Comprehensive Cancer Center.

9 Nov 2010